ArticleDermatology practical & conceptual2025
Dupilumab: an Additional Arrow in the Quiver for Prurigo Nodularis? Data From a Real-Life Setting.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrurigo nodularis (PN) management remains a significant challenge due to its chronicity, treatment resistance, and scarcity of approved treatments and to its impact on patients' quality of life.
objectiveThe aim of this study was to assess PN therapeutic management in a real-life setting.
methodsIn this prospective observational study, 90 patients diagnosed with moderate-to-severe PN were included. Patients were each prescribed therapies available for PN according to symptom severity, consistent with treatment guidelines; only those undergoing systemic therapies were included. Disease severity was evaluated through the measurements of Investigator's Global Assessment (IGA) score, Numeric Rating Scale (NRS) for pruritus, and Dermatology Life Quality Index (DLQI) at the beginning of the study (week 0 - W0 ) and after a 6-month period of treatment (W24).
resultsAt W0, patients were prescribed antidepressants (41.0%), dupilumab (34.0%), antihistamines (23.0%), phototherapy (4.0%) or nemolizumab (2.0%). At W24, patients on dupilumab achieved an IGA score of 0 or 1 and a ≥4-point NRS reduction, more than those on antidepressants (44.5% vs 16.7% and 54.4% vs 16.7%, respectively). The average DLQI score was reduced by 14 points in the dupilumab group, compared to a 6-point reduction in the antidepressant group.
conclusionsOur findings reflect the real-world practice of treating PN and support the use of dupilumab as a new effective treatment option, with significant improvements in pruritus, quality of life, and disease severity compared to antidepressant therapy, suggesting its potential as a preferred therapeutic option for PN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.